Brought to you by 
Specialty firm Watson to promote Debiopharm's Trelstar
13 Oct 2004
Executive Summary
The urology sales force of Watson Pharmaceuticals (markets branded and generic drugs) will exclusively market two approved urology products for Debiopharm SA (Swiss company that in-licenses preclinical candidates to take through development) in the US and Canada.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Specialty firm Watson to promote Debiopharm's Trelstar
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice